Idorsia IDIA

SWX: IDIA | ISIN: CH0363463438 20/03/2026

3,150 CHF (+2,27%)

(+2,27%) 20/03/2026

Grafiek Idorsia Ltd

Grafiek Idorsia Ltd

1 dag1d 2,27%
1 week1w 7,51%
1 maand1m -13,82%
3 maanden3m -28,81%
6 maanden6m -15,55%
1 jaar1j 187,93%
5 jaar5j -88,01%

Idorsia Ltd in het nieuws

Toon enkel gratis nieuws

16 maart 2026 · Idorsia announces management change · Persbericht

10 maart 2026 · Idorsia expands QUVIVIQ’s global footprint through new partnership with Pharmalink · Persbericht

26 februari 2026 · Idorsia reports strong 2025 results with QUVIVIQ sales more than doubling – further sales growth ahead with multiple pipeline catalysts in 2026 · Persbericht

12 februari 2026 · Invitation to Idorsia's FY 2025 Financial Reporting webcast and conference call · Persbericht

6 februari 2026 · Clear route to registration positions lucerastat as the potential first oral therapy for all patients with Fabry disease · Persbericht

30 januari 2026 · Idorsia to present long-term lucerastat data and kidney biopsy results at WORLDSymposium · Persbericht

28 januari 2026 · Global expansion of Idorsia’s QUVIVIQ continues with EMS partnership for Latin America · Persbericht

12 januari 2026 · Idorsia to present at J.P. Morgan 2026 Healthcare Conference · Persbericht

12 januari 2026 · Nature Communications reports promising effect of Idorsia’s lucerastat on kidney function in Fabry disease · Persbericht

6 januari 2026 · Idorsia initiates a proof-of-concept trial with its oral first-in-class selective CCR6 antagonist · Persbericht

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe